VISTAGEN THERAPEUTICS, INC. Preferred Stock Dividends, Income Statement Impact
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Preferred Stock Dividends, Income Statement Impact of $0 for the 12-month period ending 2023-03-31, per its 10-K filed 2023-06-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2023-06-28
- VISTAGEN THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2023-03-31 was $0.00.
- VISTAGEN THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. preferred stock dividends, income statement impact for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- VISTAGEN THERAPEUTICS, INC. preferred stock dividends, income statement impact for fiscal 2022 was $945.10K, a 31.79% decline from fiscal 2021.
- VISTAGEN THERAPEUTICS, INC. preferred stock dividends, income statement impact for fiscal 2021 was $1.39M.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 3 month as first filed | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|---|
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $0.00 derived: sum of 2 quarters · filed 2023-06-28 | $0.00 derived: sum of 3 quarters · filed 2023-06-28 | $0.00 10-K · filed 2023-06-28 | |
| 2022-12-31 | $0.00 10-Q · filed 2023-02-07 | $0.00 derived: sum of 2 quarters · filed 2023-02-07 | $0.00 10-Q · filed 2023-02-07 | $0.00 derived: sum of 4 quarters · filed 2023-06-28 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 3 quarters · filed 2023-06-28 | $208.00K derived: sum of 4 quarters · filed 2023-06-28 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 2 quarters · filed 2023-06-28 | $208.00K derived: sum of 3 quarters · filed 2023-06-28 | $583.00K derived: sum of 4 quarters · filed 2023-06-28 | |
| 2022-03-31 | $0.00 10-K · filed 2023-06-28 | $208.00K derived: sum of 2 quarters · filed 2023-06-28 | $583.00K derived: sum of 3 quarters · filed 2023-06-28 | $945.10K 10-K · filed 2023-06-28 | |
| 2021-12-31 | $208.00K 10-K · filed 2023-06-28 | $208.10K 10-Q · filed 2022-02-10 | $583.00K derived: sum of 2 quarters · filed 2023-06-28 | $945.10K 10-Q · filed 2023-02-07 | $1.29M derived: sum of 4 quarters · filed 2023-06-28 |
| 2021-09-30 | $375.00K 10-K · filed 2023-06-28 | $375.20K 10-Q · filed 2021-11-10 | $737.00K 10-Q · filed 2022-11-10 | $1.09M derived: sum of 3 quarters · filed 2023-06-28 | $1.44M derived: sum of 4 quarters · filed 2023-06-28 |
| 2021-06-30 | $362.00K 10-K · filed 2023-06-28 | $711.00K derived: sum of 2 quarters · filed 2023-06-28 | $1.06M derived: sum of 3 quarters · filed 2023-06-28 | $1.41M derived: sum of 4 quarters · filed 2023-06-28 | |
| 2021-03-31 | $349.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-23 | $702.60K derived: sum of 2 quarters · filed 2022-06-23 | $1.05M derived: sum of 3 quarters · filed 2022-06-23 | $1.39M 10-K · filed 2022-06-23 | |
| 2020-12-31 | $353.60K 10-Q · filed 2022-02-10 | $700.80K derived: sum of 2 quarters · filed 2022-02-10 | $1.04M 10-Q · filed 2022-02-10 | ||
| 2020-09-30 | $347.20K 10-Q · filed 2021-11-10 | $683.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |